TScan Therapeutics (TCRX) has issued an update.
At TScan Therapeutics’ Annual Meeting on June 12, 2024, significant board changes were made as Timothy Barberich stepped down as Chairman and board member, with Stephen Biggar taking over as Chairman. Garry Nicholson joined as an independent director and received an option grant for company shares, aligning with the company’s compensation policy. Additionally, the stockholders approved an amended equity incentive plan, increasing available shares and including pre-funded warrants in annual share replenishment calculations. The meeting also saw the election of Class III directors and the ratification of the company’s independent accounting firm.
See more insights into TCRX stock on TipRanks’ Stock Analysis page.
